236 related articles for article (PubMed ID: 19904267)
1. Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.
Wagner AD; Buechner-Steudel P; Moehler M; Schmalenberg H; Behrens R; Fahlke J; Wein A; Behl S; Kuss O; Kleber G; Fleig WE
Br J Cancer; 2009 Dec; 101(11):1846-52. PubMed ID: 19904267
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
3. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of combination chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced cancers of the bile duct, gallbladder, and ampulla of Vater.
Sohn BS; Yuh YJ; Kim KH; Jeon TJ; Kim NS; Kim SR
Tumori; 2013; 99(2):139-44. PubMed ID: 23748804
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers.
Verderame F; Russo A; Di Leo R; Badalamenti G; Santangelo D; Cicero G; Valerio MR; Gulotta G; Tomasello G; Gebbia N; Fulfaro F
Ann Oncol; 2006 Jun; 17 Suppl 7():vii68-72. PubMed ID: 16760298
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
[TBL] [Abstract][Full Text] [Related]
8. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
[TBL] [Abstract][Full Text] [Related]
9. INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial.
Patt YZ; Murad W; Fekrazad MH; Baron AD; Bansal P; Boumber Y; Steinberg K; Lee SJ; Bedrick E; Du R; Lee FC
Cancer Med; 2017 Sep; 6(9):2042-2051. PubMed ID: 28801995
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.
Hezel AF; Noel MS; Allen JN; Abrams TA; Yurgelun M; Faris JE; Goyal L; Clark JW; Blaszkowsky LS; Murphy JE; Zheng H; Khorana AA; Connolly GC; Hyrien O; Baran A; Herr M; Ng K; Sheehan S; Harris DJ; Regan E; Borger DR; Iafrate AJ; Fuchs C; Ryan DP; Zhu AX
Br J Cancer; 2014 Jul; 111(3):430-6. PubMed ID: 24960403
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.
Knox JJ; Hedley D; Oza A; Siu LL; Pond GR; Moore MJ
Ann Oncol; 2004 May; 15(5):770-4. PubMed ID: 15111345
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Wagner AD; Buechner-Steudel P; Wein A; Schmalenberg H; Lindig U; Moehler M; Behrens R; Kleber G; Kuss O; Fleig WE
Ann Oncol; 2007 Jan; 18(1):82-87. PubMed ID: 17030546
[TBL] [Abstract][Full Text] [Related]
14. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
[TBL] [Abstract][Full Text] [Related]
15. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.
Meyerhardt JA; Zhu AX; Stuart K; Ryan DP; Blaszkowsky L; Lehman N; Earle CC; Kulke MH; Bhargava P; Fuchs CS
Dig Dis Sci; 2008 Feb; 53(2):564-70. PubMed ID: 17597402
[TBL] [Abstract][Full Text] [Related]
16. A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
Lassen U; Jensen LH; Sorensen M; Rohrberg KS; Ujmajuridze Z; Jakobsen A
Acta Oncol; 2011 Apr; 50(3):448-54. PubMed ID: 20670085
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma.
Qin TJ; Zhao XH; Yun J; Zhang LX; Ruan ZP; Pan BR
World J Gastroenterol; 2008 Sep; 14(33):5210-6. PubMed ID: 18777599
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine-cisplatin versus gemcitabine-oxaliplatin doublet chemotherapy in advanced gallbladder cancers: a match pair analysis.
Ramaswamy A; Ostwal V; Pinninti R; Kannan S; Bhargava P; Nashikkar C; Mirani J; Banavali S
J Hepatobiliary Pancreat Sci; 2017 May; 24(5):262-267. PubMed ID: 28196310
[TBL] [Abstract][Full Text] [Related]
19. Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma.
Cassier PA; Thevenet C; Walter T; Baulieux J; Scoazec JY; Bancel B; Adham M; Souquet JC; Ponchon T; Lombard-Bohas C
Eur J Gastroenterol Hepatol; 2010 Sep; 22(9):1111-7. PubMed ID: 20386107
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial.
Nehls O; Oettle H; Hartmann JT; Hofheinz RD; Hass HG; Horger MS; Koppenhöfer U; Hochhaus A; Stieler J; Trojan J; Gregor M; Klump B
Br J Cancer; 2008 Jan; 98(2):309-15. PubMed ID: 18182984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
